Organogenesis is weathering a tough market storm, with advanced wound care sales plummeting 61% year-over-year due to shifting Medicare coverage policies — but there’s hope on the horizon. Despite a 58% overall revenue drop in Q2, net product revenue surged 18% quarter-over-quarter, fueled by a 23% uptick in advanced wound care and a 30% jump in unit volume for their PMA-approved biologic, Apligraf. The company sees CMS’s recent moves as a step toward evidence-based care, positioning Organogenesis — with its robust clinical data and diverse portfolio — to thrive. They’re also expanding into new markets with ReNu’s Amnuvx for knee osteoarthritis and publishing strong results for PuraPly AM in diabetic foot ulcers. To navigate slower recovery, they’ve cut 138 jobs and revised full-year guidance to reflect a more cautious outlook, projecting a 62–68% revenue decline year-over-year.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
